What is Xencor?
Headquartered in Pasadena, California, Xencor specializes in the engineering of monoclonal antibodies and cytokine therapeutics. Since its inception in 1997, the company has focused on addressing significant unmet medical needs in oncology and autoimmune diseases. By leveraging its XmAb technology, Xencor has established a robust pipeline of therapeutic candidates, positioning itself as a critical player in the biopharmaceutical sector. The company's business model relies on both internal development and strategic partnerships to advance its clinical programs through the regulatory landscape.
How much funding has Xencor raised?
Xencor has raised a total of $237.2M across 7 funding rounds:
Series B
$12.3M
Series C
$50M
Series D
$10M
Series E
$60M
Debt
$7.5M
Stock Offering
$72.4M
Share Placement
$25M
Series B (1999): $12.3M with participation from Stafford Capital Partners
Series C (2000): $50M led by Sands Brothers Asset Management, Stafford Capital Partners, and Moore Capital
Series D (2005): $10M supported by Zen Investments
Series E (2007): $60M featuring Merlin Nexus, MedImmune Ventures, Zen Investments, Oxford Bioscience Partners, and Novo Nordisk
Debt (2010): $7.5M, investors not publicly disclosed
Stock Issuance/Offering (2013): $72.4M, investors not publicly disclosed
Share Placement (2021): $25M, investors not publicly disclosed
Key Investors in Xencor
Oxford Bioscience Partners
Oxford Bioscience Partners is an international venture capital firm specializing in life science technology based investments, with offices in Boston, Massachusetts and Seoul, Korea.
Moore Capital
Moore Capital, LLC is committed to maximizing the value of our private equity investments as well as helping our partners achieve optimum success through a commitment to hard work, professional service, and confidentiality.
MedImmune Ventures
MedImmune Ventures is the venture capital arm of a major biopharmaceutical organization, focusing on early-to-mid-stage investments in innovative healthcare and life science companies.
What's next for Xencor?
With the recent influx of capital, Xencor is well-positioned to accelerate its clinical-stage programs and expand its research and development capabilities. The company is expected to prioritize the advancement of its lead candidates through late-stage trials, potentially enhancing its competitive edge in the monoclonal antibody market. Future strategic initiatives will likely focus on optimizing its cytokine therapeutic portfolio and exploring new collaborative opportunities to maximize the commercial potential of its proprietary platform. As the firm matures, the focus will shift toward regulatory milestones and the potential for long-term value creation for its stakeholders.
See full Xencor company page
